A Curious Union: Covid, Clorox, Cleveland Clinic, and the CDC Foundation nakedcapitalism.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nakedcapitalism.com Daily Mail and Mail on Sunday newspapers.
(1)
LAS VEGAS, NV / ACCESSWIRE / January 25, 2021 / GB Sciences, Inc. (OTCQB:GBLX), through GBS Global Biopharma, Inc. ( GBS ), has executed a Sponsored Research Agreement with Michigan State University (MSU) to obtain valuable proof-of-concept data to support the use of their new proprietary cannabinoid containing complex mixtures (CCCM) for the treatment of Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS) in COVID-19 patients. CRS, MAS, and ARDS are the leading causes of deaths in COVID-19 patients. GBS CCCM were designed to reduce the life-threatening levels of specific cytokines and pro-inflammatory processes triggered by SARS-CoV-2 infections, while preserving those immune functions and cytokines that are necessary for fighting the viral infection.